Several New Studies Presented at ECCMIC 2022 Confirm Veklury® Activity in Treating COVID-19 Pharmaceutical Investing
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH Pharmaceutical Investing
ABBV SHAREHOLDER ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV Pharmaceutical Investing
AUPH INVESTOR NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH Pharmaceutical Investing
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV Pharmaceutical Investing
Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class Action Filed Against of Investors of AbbVie, Inc. Pharmaceutical Investing
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aurinia and Playstudios and Encourages Investors to Contact the Firm Pharmaceutical Investing
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stronghold, AbbVie, Twitter, and Li-Cycle and Encourages Investors to Contact the Firm Pharmaceutical Investing
DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH Pharmaceutical Investing
Aurinia Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Lawsuit Against Aurinia Pharmaceuticals Inc. Pharmaceutical Investing
CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Shareholders of Securities Fraud Class Action Lawsuit Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
